In our Supply Chain and Manufacturing slide deck, EUDRAC have summarised key responsibilities for Marketing Authorisation Holders with regards to Medicinal Products’ Quality and Distribution requirements after 01 January 2021, given no free trade agreement is in place.
Read moreWith the UK/EU free trade agreement still subject to intense negotiations, we have summarized what a No-deal scenario would mean for Marketing Authorisations of Centrally Authrorised Products.
Read moreEUDRAC is launching new regulatory activity in the field of Health and Beauty to help manufacturers, distributors and marketers of Cosmetics Overview Cosmetics can be classified differently depending on various factors, such as intended use, mode of action and – importantly – local regulatory...
Read moreThis article covers some important highlights from the MHRA Good Pharmacovigilance Practise (GPVP) Symposium held in London on 11 February 2020. The symposium provided a mixture of inspector-specific insights through the presentation of trends and metrics from inspection findings, and some...
Read moreIn September 2019 EMA began a review under Article 5(3) of Regulation (EC) No 726/2004 to provide guidance to MAHs on how to avoid the presence of nitrosamine impurities in human medicines. As part of this review, the MAHs were requested to review their authorised human medicines containing...
Read moreAfter a successful test phase, ANSM has decided to maintain its two accelerated circuits for medicinal product clinical trial authorisations (Fast Track). These circuits were established on 15 October 2018 as an initial test run and on a voluntary basis to reduce clinical trial authorisation...
Read moreThis website uses cookies to ensure you get the best experience on our website. Read more.